Danaos Corp
Danaos Corp (DAC) Stock News
The latest DAC headlines and market coverage — 3 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
ImPact Biotech Presents Updated Data from Phase 1 Trial of Padeliporfin VTP in LA-PDAC and Phase 3 ENLIGHTED Trial in LG-UTUC at ASCO 2026
ImPact Biotech announced updated clinical trial data for Padeliporfin VTP, a vascular-targeted photodynamic therapy. In the Phase 1 LA-PDAC trial, 71% of patients (5/7) achieved successful surgical resection with a well-tolerated safety profile. The Phase 3 ENLIGHTED trial in LG-UTUC showed 70% complete response rates with 85.7% of patients sustaining responses for at least 12 months. The company plans to submit an NDA for LG-UTUC in 2027 and is exploring potential accelerated registrational pathways for LA-PDAC.
- GlobeNewswire Inc.·
SCOR successfully sponsors a new catastrophe bond, Atlas Capital DAC Series 2026-1
SCOR has successfully sponsored a new catastrophe bond (Atlas Capital DAC Series 2026-1) providing USD 75 million in multi-year risk transfer capacity to protect against named storms, earthquakes, and European windstorms from June 2026 to May 2029. The bond was priced at 6.00% interest spread and well-received by investors, marking the fourth issuance using the Atlas Capital DAC vehicle since 2023.
- GlobeNewswire Inc.·
SCOR place avec succès une nouvelle obligation catastrophe, Atlas Capital DAC Series 2026-1
SCOR has successfully issued a new catastrophe bond (Atlas Capital DAC Series 2026-1) providing USD 75 million in multi-year coverage against natural disasters including US and Caribbean storms, earthquakes, and European storms through May 2029. The bond was priced at 6.00% and well-received by investors. This is the fourth issuance using the Atlas Capital DAC vehicle, demonstrating efficiency gains and supporting SCOR's Risk Partnerships strategy under its Forward 2026 plan.